Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca In Buy Now, Pay In Full Later Deal For Majority Acerta Stake

This article was originally published in Scrip

Executive Summary

In a move which AstraZeneca PLC says "completes its transformation in oncology," it is acquiring a 55% stake in privately held Dutch biotech Acerta Pharma BV for $4bn, made up of $2.5bn now and $1.5bn later. The deal also includes an option to acquire the remainder of the company for a further $3bn.


Related Content

Finance Watch: Government Grants Galore And Other New Funding Sources
Lysosomal Storage Disorders: Azafaros Takes Aim At Small Molecules
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica
BioGeneration Ventures Leads Europe's Seed Investing With New Fund
Fast-To-Market Play For AstraZeneca's Acalabrutinib With MCL Filing
Bio Boost For Benelux As BioGeneration Ventures Beats Fund Target





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts